Member Info for Hibas19

It's become a really frustrating share to hold. They've dropped a fair bit of good news over the past year, the share price just keeps tanking. I appreciate the sale announced this week isn't a done deal yet, but is the company really worth less than it was before the deal was announced? (28.56p v 28.34p per share - google so maybe not completely accurate).

Not long until the results, though it feels like even if that's fantastic, the share price won't reflect it. I can only guess someone is selling into the rise. Hoping it's not canaccord selling down as they hold a lot of shares...

good luck to all holders

NHS supply chain have finally posted the case study on their website. https://www.supplychain.nhs.uk/news-article/novel-technology-improves-outcome-for-patients-with-complex-polyps/

i've seen a lot of noise about when the nice guidelines are due, by their own time lines would expect it to be in march, but according to chris han**** at the proactive investor conference in jan, results were still 6 months away (at around 16.5 minutes in https://youtu.be/fm0486bmyum?si=nvdyaky1pfgnieww). think we may still have a bit of a wait, but hoping for good news when it does land

Canaccord reduced their position, they sold down

But to actually answer your question, yes think the NICE news would be very positive for the share price when it does land

Think it might be more to do with this news https://www.rbhh-specialistcare.co.uk/news/ion-robot-lung-tumour

Not convinced NICE stick to their own guidelines, but could be pleasantly surprised

Not the best trading update...

Not seen any tips, they do have results due soon (released mid Feb last year) and given they submitted for Fda approval for the SLE6000 ventilator almost 6 months ago expecting an update on that fairly soon too. I think it was oversold and was overdue a rerate anyway

Does anyone know if CREO has a capital markets day on Nov 7th? I thought there was but now can't find any info on it

Agreed, feels really significant. Be interested to see whether this leads to a revision on when CREO expects to achieve breakeven point.

Market response doesn't seem to agree with my views on this bit of news, but it's a bit of a sh*tshow out there at the moment so trying not to take it as personal to CREO. I guess until the approvals actually come from Europe and the US, it's a nice to know, but not 100% , so when we actually get those approvals that's when it will get priced in to the share price. At least I hope so, watching this bob along at 32p-35P is frustrating at times

There was an incident on the London stock exchange on the 19th, trading in lots of stocks were halted, resumed on the 20th.

Agreed, really frustrating. I thought I had a bargain when I bought and have had to heavily average down. Hoping now that we should be funded to profitability, with the amount of news to potentially drop (eg fda approval for spydrblade should be due this year- according to a proactive video) & hopefully some positive numbers on adoption we can get back to where we should be (and i can have shares back in profit).

Don't know the highest market cap so far, but they released an rns 30th April 2021, number of shares in issue at that date were 157, 940, 390, share price was 1. 9863, so market cap of around 313.7m

Were we supposed to get a trading update today? The rns about the investor day mentioned it would include a trading update, would they would not also have to also rns the update? Unless I've misunderstood the rns..

FYI -
https://docs.publicnow.com/viewDoc?hash_primary=6284D09D9F75FD4E01273F34DE955F896153ADA5

Link above is a new Creo market presentation from the following: https://www.marketscreener.com/quote/stock/CREO-MEDICAL-GROUP-PLC-32411263/news/Creo-Medical-Corporate-Presentation-Q3-2022-42273271/

they don't give enough information with the partnership deals in order to help us determine where they are. Everything is really opaque, which isn't great in any circumstance, but especially not in a market like this and the share price seems to be suffering the consequences. Appreciate deals are sensitive in nature, especially if they are still negotiating others, but they haven't even told us if there has been any upfront payments (which could negate the need for a fundraise).
The lack of transparency is really frustrating, if they don't want to tell us the exact royalties they could at least say "low single digit to low double digit tiered royalties", give a total for milestone payments if they don't want to list them individually and an idea of partnership length so we can get an idea of when we expect to start seeing results. The pharma companies manage to give this level of information when they announce deals, not sure why Creo can't.